Actively Recruiting
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
Led by Kliniken Essen-Mitte · Updated on 2026-05-08
60
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
Sponsors
K
Kliniken Essen-Mitte
Lead Sponsor
K
Karl and Veronica Carstens Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Triple-negative breast cancer (TNBC) is considered a tumor with a high risk of recurrence and metastasis and requires aggressive systemic therapy combining immunotherapy and chemotherapy. If the therapy leads to complete remission (pCR), this is prognostically beneficial for patients. Studies demonstrating the influence of the microbiome on the development of cancer and on the efficacy and toxicity of immunotherapy and chemotherapy underscore the potential of targeted nutritional interventions. Current data from microbiome research indicate that a high-fiber, gut-healthy diet modulates the microbiota in such a way that the response to and toxicity of immunotherapy and chemotherapy could be improved. The aim of this project is to translate these findings into clinical care. The study will investigate whether an online integrative oncology group training program with mind-body elements supports and is feasible for the implementation of a high-fiber diet in patients with TNBC undergoing neoadjuvant immunotherapy and chemotherapy. The program will be compared with a control group that receives a flyer with nutritional recommendations. If the feasibility of this complementary medicine approach can be demonstrated, a confirmatory study is planned to investigate the expected effect on the pathological complete remission of TNBC.
CONDITIONS
Official Title
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 to 75 years
- Histologically confirmed diagnosis of non-metastatic triple-negative breast cancer (TNM stage I-III)
- Planned neoadjuvant chemotherapy and immunotherapy
- Willingness to participate and signed consent form
You will not qualify if you...
- Advanced stage of disease with metastases
- Severe physical or psychopharmacologically treated psychiatric comorbidity preventing participation
- Pregnancy
- Participation in other clinical studies with behavioral, psychological, or complementary interventions
- Diet incompatible with high-fiber diet, such as ketogenic diet
- Drug and/or alcohol abuse
- Inability to complete questionnaires independently
- History of colectomy
- Gastrointestinal stenosis
- Fructose intolerance
- Histamine intolerance
- Gluten intolerance
- Unwillingness to refrain from probiotics during study
- Eating disorders
- No laptop or camera available for online training
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Evang. Kliniken Essen-Mitte gGmbH
Essen, North Rhine-Westphalia, Germany, 45276
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here